These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22626577)

  • 21. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burden of overactive bladder symptom on quality of life in stroke patients.
    Itoh Y; Yamada S; Konoeda F; Koizumi K; Nagata H; Oya M; Suzuki N
    Neurourol Urodyn; 2013 Jun; 32(5):428-34. PubMed ID: 23129306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome.
    Chung SD; Liao CH; Chen YC; Kuo HC
    Neurourol Urodyn; 2011 Sep; 30(7):1300-4. PubMed ID: 21560153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obese children at higher risk for having overactive bladder symptoms: a community-based study.
    Chang SJ; Chiang IN; Lin CD; Hsieh CH; Yang SS
    Neurourol Urodyn; 2015 Feb; 34(2):123-7. PubMed ID: 24273112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence and risk factors of OAB in middle-aged and old people in China.
    Wen JG; Li JS; Wang ZM; Huang CX; Shang XP; Su ZQ; Lu YT; Suo ZH; Wang Y; Qin GJ; Zhang WX; Heesakkers JP
    Neurourol Urodyn; 2014 Apr; 33(4):387-91. PubMed ID: 23765684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The natural history of the overactive bladder syndrome in females: a long-term analysis of a health screening project.
    Heidler S; Mert C; Temml C; Madersbacher S
    Neurourol Urodyn; 2011 Nov; 30(8):1437-41. PubMed ID: 21661037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Lin H; Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of discontinuing overactive bladder medications.
    Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
    BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and associated factors of overactive bladder in Korean children 5-13 years old: a nationwide multicenter study.
    Chung JM; Lee SD; Kang DI; Kwon DD; Kim KS; Kim SY; Kim HG; Moon du G; Park KH; Park YH; Pai KS; Suh HJ; Lee JW; Cho WY; Ha TS; Han SW;
    Urology; 2009 Jan; 73(1):63-7; discussion 68-9. PubMed ID: 18829077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of overactive bladder after vaginal hysterectomy and associated repairs for pelvic organ prolapse.
    Diez-Itza I; Aizpitarte I; Becerro A; Sarasqueta C
    Gynecol Obstet Invest; 2009; 68(1):65-70. PubMed ID: 19407458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women.
    Teleman PM; Lidfeldt J; Nerbrand C; Samsioe G; Mattiasson A;
    BJOG; 2004 Jun; 111(6):600-4. PubMed ID: 15198789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The natural history of overactive bladder and stress urinary incontinence in older women in the community: a 3-year prospective cohort study.
    Donaldson MM; Thompson JR; Matthews RJ; Dallosso HM; McGrother CW;
    Neurourol Urodyn; 2006; 25(7):709-16. PubMed ID: 16998862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High frequency of overlap between functional dyspepsia and overactive bladder.
    Matsuzaki J; Suzuki H; Fukushima Y; Hirata K; Fukuhara S; Okada S; Hibi T
    Neurogastroenterol Motil; 2012 Sep; 24(9):821-7. PubMed ID: 22616664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prevalence of probable overactive bladder, associated risk factors and its effect on quality of life among Turkish midwifery students.
    Özgür Yeniel A; Mete Ergenoglu A; Meseri R; Hadimli A; Askar N; Mete Itil I
    Eur J Obstet Gynecol Reprod Biol; 2012 Sep; 164(1):105-9. PubMed ID: 22762841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of symptoms with urodynamic findings in men with overactive bladder syndrome.
    Al-Zahrani AA; Gajewski JB
    BJU Int; 2012 Dec; 110(11 Pt C):E891-5. PubMed ID: 22928556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the prognostic factors for overactive bladder symptoms following surgical treatment in patients with benign prostatic obstruction.
    Seki N; Yuki K; Takei M; Yamaguchi A; Naito S
    Neurourol Urodyn; 2009; 28(3):197-201. PubMed ID: 18973143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Demographic distribution and prevalence of overactive bladder in Venezuela].
    Dávila HA; López V; Nieves L; Colantuono A; Guaiquirián L; Sánchez P; Kaufman A; Acosta F; Mack S; Marcano N; Martínez C; Toro J; Moreira O; Hernández M; Kanski A; Delgado J; Sánchez-Salas R
    Actas Urol Esp; 2010 Feb; 34(2):176-80. PubMed ID: 20403282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?
    Boettcher M; Haselhuhn A; Jakse G; Brehmer B; Kirschner-Hermanns R
    BJU Int; 2012 Jun; 109(12):1824-30. PubMed ID: 21952039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.